Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163180 | 0.78 | LMNA (0.59) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL4408444 | 0.78 | LMNA (0.59) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL1318724 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL950306 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL4527137 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL3035928 | 0.77 | LMNA (0.62) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL3261613 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL27333607 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL4405417 | 0.77 | LMNA (0.53) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL6362505 | 0.76 | P2RX7 (0.70) | LMNAP2RX7ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279737-B1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-8148540-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ASTRAZENECA (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-09-01 | — | — | US | disclosed |
| EP-2279737-A1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2011-02-02 | — | — | EP | disclosed |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-01-27 | — | — | US | disclosed |
| EP-1480644-B1 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | NOVEXEL (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-7732610-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-1307457-B1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2004-04-07 | — | — | EP | disclosed |
| CN-1468242-A | Azabicyclic compounds, method for the production thereof, and use thereof as medicaments, in particular as antibacterials | ���ĵ�˹ҩƷ��˾ | 2004-01-14 | — | — | CN | disclosed |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003063864-A2 | HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | WO | disclosed |
| EP-1307457-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2003-05-07 | — | — | EP | disclosed |
| EP-1282621-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma S.A. (FR) | 2003-02-12 | — | — | EP | disclosed |
| WO-2002010172-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001085729-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA S.A. (FR) | 2001-11-15 | — | — | WO | disclosed |
| EP-0114128-B1 | 3-AMINO-2-OXO-AZETIDINE DERIVATIVES CONTAINING IN POSITION 1 A NITROGEN HETEROCYCLIC RADICAL, PROCESS FOR THEIR PREPARATION, THEIR USE AS THERAPEUTICAL AGENTS AND INTERMEDIATES FOR THEIR PREPARATION | ROUSSEL-UCLAF (FR) | 1989-03-22 | — | — | EP | disclosed |
| EP-0114128-A1 | 3-Amino-2-oxo-azetidine derivatives containing in position 1 a nitrogen heterocyclic radical, process for their preparation, their use as therapeutical agents and intermediates for their preparation | ROUSSEL-UCLAF (FR) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | LMNA 544/4885P2RX7 3813/4885ALDH1A1 380/4885 |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | LMNA 1791/4885P2RX7 508/4885ALDH1A1 2392/4885 |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | LMNA 544/4885P2RX7 3813/4885ALDH1A1 380/4885 |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | LMNA 1791/4885P2RX7 508/4885ALDH1A1 2392/4885 |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | AZI2, NISCH, DCTPP1 | LMNA 2341/4885P2RX7 756/4885ALDH1A1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.